Despite advances in the diagnosis and treatment of osteogenesis imperfecta, more research
is needed. Bisphosphonate treatment decreases long-bone fracture rates, but such fractures …

Background Children with osteogenesis imperfecta are often treated with intravenous
bisphosphonates. We aimed to assess the safety and efficacy of risedronate, an orally …

Osteogenesis imperfecta (OI) is the term used to describe a group of rare inherited skeletal
disorders characterized by a greatly increased risk of fragility fractures (1). Mutations in …

Osteogenesis imperfecta (OI), or brittle bone disease, is a heterogeneous disorder
characterised by bone fragility, multiple fractures, bone deformity, and short stature. OI is a …

Bisphosphonates, used for a long time in osteoporosis management, are currently the target
of intensive research, from pre-formulation studies to more advanced stages of clinical …

Several genetic disorders affecting bone mineralization may manifest during dentin
mineralization. Dentin and bone are similar in several aspects, especially pertaining to the …

Context: Fibrous dysplasia (FD) is a rare skeletal disorder, resulting in deformity, fracture,
functional impairment, and pain. Bisphosphonates have been advocated as a potential …

The aim of this Task Force was to review the use of dual-energy X-ray absorptiometry (DXA)
in children and adolescents with underlying chronic diseases that pose risk factors for …

Aim To investigate the impact of new evidence for weight‐bearing, bisphosphonates, and
vitamin D and calcium interventions, towards updating the systematic review and clinical …

Bisphosphonates are widely used off‐label in the treatment of patients with osteogenesis
imperfecta (OI) with the intention of reducing the risk of fracture. Although there is strong …